Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicentre retrospective cohort in daily practice.

A LasekN BellonS MalletE PuzenatA C BursztejnC AbasqMazereeuw-Hautier Juliette Christine ChiaveriniT HubicheNadia Raison-PeyronA Du ThanhSébastien Barbarot Hélène AubertZ ReguiaiCatherine DroitcourtC FievetA BellissenM BachelerieA NosbaumA LeymarieP ArmingaudM Masson RegnaultEmmanuel Mahénull nullnull null

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)

These real-life data confirm the efficacy and safety of dupilumab in children with moderate to severe AD extended to dyshidrosis and atopic prurigo, but it also revealed a lower frequency of DFR and conjunctivitis. However, administration in injectable form may be a barrier in this age group.

Keyphrases

atopic dermatitis
young adults
electronic health record
primary care
big data
cross sectional
clinical trial
physical activity
study protocol
early onset
randomized controlled trial
high intensity
machine learning
data analysis
double blind
drug induced